The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease
Abstract
Background — Sympathetic tone is consistently raised in patients with end-stage renal disease (ESRD). We therefore tested the hypothesis that sympathetic activation is associated with mortality and cardiovascular events in a cohort of 228 patients undergoing chronic hemodialysis who did not have congestive heart failure at baseline and who had left ventricular ejection fraction >35%. Methods and Results — The plasma concentration of norepinephrine (NE) was used as a measure of sympathetic activity. Plasma NE exceeded the upper limit of the normal range (cutoff 3.54 nmol/L) in 102 dialysis patients (45%). In a multivariate Cox regression model that included all univariate predictors of death as well as the use of sympathicoplegic agents and β-blockers, plasma NE proved to be an independent predictor of this outcome (hazard ratio [1-nmol/L increase in plasma NE]: 1.07, 95% CI 1.01 to 1.14, P =0.03). Similarly, plasma NE emerged as an independent predictor of fatal and nonfatal cardiovascular events (hazard ratio [1-nmol/L increase in plasma NE] 1.08, 95% CI 1.02 to 1.15, P =0.01) in a model that included previous cardiovascular events, pulse pressure, age, diabetes, smoking, and use of sympathicoplegic agents and β-blockers. The adjusted relative risk for cardiovascular complications in patients with plasma NE >75th percentile was 1.92 (95% CI 1.20 to 3.07) times higher than in those below this threshold ( P =0.006). Conclusions — Sympathetic nerve overactivity is associated with mortality and cardiovascular outcomes in ESRD. Controlled trials with antiadrenergic drugs are needed to determine whether interference with the sympathetic system could reduce the high cardiovascular morbidity and mortality in dialysis patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ongoing systemic sympathetic activation has long been thought to be noxious, in heart failure 18,19 and renal failure.113”
From Obesity Paradox in Hypertension: Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form? (2018) · cites this paper as [113]
In the citing paper
“A striking observation is that of Zoccali and colleagues, who demonstrated the plasma concentration of norepinephrine to predict the incidence of cardiovascular events, and survival, in patients with end-stage renal disease10.”
From The Sympathetic Nervous System Alterations in Human Hypertension (2015) · cites this paper as [10]
Citations
Cites
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125
Rozanski, A., Blumenthal, J. A., & Kaplan, J. (1999) · Circulation · doi:10.1161/01.cir.99.16.2192 · Cited by 2,846
Block, G. A., Hulbert‐Shearon, T. E., Nw, L., & Port, F. K. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9531176 · Cited by 2,347
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Premature cardiovascular disease in chronic renal failure
Baigent, C., Burbury, K., & Wheeler, D. C. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02456-9 · Cited by 581
The prognostic importance of left ventricular geometry in uremic cardiomyopathy.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barré, P. E. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v5122024 · Cited by 480
Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage
Mancia, G., Grassi, G., Giannattasio, C., & Seravalle, G. (1999) · Hypertension · doi:10.1161/01.hyp.34.4.724 · Cited by 471
How to assess sympathetic activity in humans
Grassi, G., & Esler, M. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917060-00001 · Cited by 455
Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barré, P. E. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v75728 · Cited by 415
Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure
Ligtenberg, G., Blankestijn, P. J., Oey, P. L., Klein, I. H. H. T., Dijkhorst-Oei, L.-T., Boomsma, F., Wieneke, G. H., van Huffelen, A. C., & Koomans, H. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401704 · Cited by 407
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–518 of 518
Hering, D., & Heuser, R. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-38934-4_17
Targeting Blood Pressure Lowering and the Sympathetic Nervous System
Hering, D., & Narkiewicz, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00013-1
Autonomic and Vascular Function in Cardiovascular Health with Insights from COVID-19
Nandadeva, D. (2024) · Sri Lanka Journal of Medicine · doi:10.4038/sljm.v33i1.496
Bertog, S. C., Vaškelytė, L., Drexel, T., Hofmann, I., Id, D., Gafoor, S. A., Reinartz, M., & Sievert, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-26219-4.00022-0
Schiavone, M. A., Castellaro, C., Redondo, J. C. P., Diaz, C. H., & Laham, G. (2024) · medRxiv · doi:10.1101/2024.09.30.24314645
Popova, A. A., Zyubanova, I. V., Игоревна, Р. Н., Mordovin, V. F., Lichikaki, V. A., Manukyan, M. A., Solonskaya, E. I., Хунхинова, С. А., Александровна, С. И., Afanasiev, S. A., et al. (2025) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2025-40-1-147-158
Georgianos, P. I., Kontogiorgos, I., Vaios, V., Leivaditis, K., & Liakopoulos, V. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00756-7
Sudden cardiac death in chronic kidney disease
Hajhosseiny, R., Khavandi, K., & Goldsmith, D. J. A. (2015) · doi:10.1093/med/9780199592548.003.0108_update_001
Gilyarevskiy, S. R., Shchedrina, A. Y., & Golshmid, M. V. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-444
Els receptors ErbB en la resposta a l’estimulació adrenèrgica crònica en el ratolí
Figueras, G. C. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Nishihara, M., Shinohara, K., Ikeda, S., Akahoshi, T., & Tsutsui, H. (2024) · Figshare · doi:10.6084/m9.figshare.26944923
Nishihara, M., Shinohara, K., Ikeda, S., Akahoshi, T., & Tsutsui, H. (2024) · Figshare · doi:10.6084/m9.figshare.26944920
Marques, P. L., Domingues, T. D., Filipe, A. I., Ferreira, R. L., Junius, G., Patteet, L., den Steen, E. V., Mateus, L. M., Galac, S., & Leal, R. O. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalaf080
Raj, P., Yu, L., Nguyen, H., Rabinovich-Nikitin, I., Thandapilly, S. J., Wigle, J. T., Zieroth, S. R., & Netticadan, T. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107174
Volume extracellulaire : évolution et valeur pronostique au cours de la maladie rénale chronique
Faucon, A. (2020) · theses.fr (ABES) · doi:10.70675/e3fa10b5zefb2z456fzb3c3z25eec1870bad
Scalise, F., Toscano, E., Sorropago, A., Amman, C., & Grassi, G. M. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_4
Beyond Kt/V: redefining dialysis adequacy as targeted cardiovascular risk reduction
Zoccali, C., Strippoli, G., Locatelli, F., Mallamaci, F., Usyat, L., & Stuard, S. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag223
Self-citationSchmieder, R. E., Kannenkeril, D., Böhm, M., Mahfoud, F., Rump, L. C., Stegbauer, J., van der Giet, M., Meyer, M. R., Schiffer, M., Veelken, R. A., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004482
Metadata
- Authors
- Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Cataliotti, A., Stancanelli, B., & Malatino, L. S.
- Affiliations
- University of Catania (IT)
- ORCID
- Venue
- Circulation
- Published
- 2002-03-19
- Volume
- 105
- Issue
- 11
- Pages
- 1354-1359
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2166904705
- Cited by
- 519
- References
- 36
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 12 · 2023: 16 · 2022: 15 · 2021: 14 · 2020: 20 · 2019: 11 · 2018: 20 · 2017: 29 · 2016: 31 · 2015: 30 · 2014: 38 · 2013: 27 · 2012: 31
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Update notices
- correction (2002-05-07)
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regione Calabria
- Topics
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- plasma norepinephrine, end-stage renal disease, hemodialysis, sympathetic activation, cardiovascular mortality, cardiovascular events, beta-blockers, cardiovascular risk prediction
- MeSH terms
- Cardiovascular Diseases, Chronic Disease, Female, Renal Dialysis, Humans, Kidney Failure, Chronic, Male, Middle Aged, Norepinephrine, Predictive Value of Tests, Risk Factors, Stroke Volume, Sympathetic Nervous System, Cohort Studies, Comorbidity, Survival Rate, Proportional Hazards Models, Survival Analysis, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review